While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .
Neurofeedback Intervention in Fibromyalgia Syndrome; a Randomized, Controlled, Rater Blind Clinical Trial
We design ed a r and omized , rater blind study to assess the efficacy of EEG Biofeedback ( Neurofeedback-NFB ) in patients with fibromyalgia syndrome ( FMS ) . Eighteen patients received twenty sessions of NFB-sensory motor rhythm ( SMR ) treatment ( NFB group ) during 4 weeks , and eighteen patients were given 10 mg per day escitalopram treatment ( control group ) for 8 weeks . Visual Analog Scales for pain and fatigue , Hamilton and Beck Depression and Anxiety Inventory Scales , Fibromyalgia Impact Question naire and Short Form 36 were used as outcome measures which were applied at baseline and 2nd , 4th , 8th , 16th , 24th weeks . Mean amplitudes of EEG rhythms ( delta , theta , alpha , SMR , beta1 and beta2 ) and theta/SMR ratio were also measured in NFB group . All post-treatment measurements showed significant improvements in both of the groups ( for all parameters p < 0.05 ) . NFB group displayed greater benefits than controls ( for all parameters p < 0.05 ) . Therapeutic efficacy of NFB was found to begin at 2nd week and reached to a maximum effect at 4th week . On the other h and , the improvements in SSRI treatment were also detected to begin at 2nd week but reached to a maximum effect at 8th week . No statistically significant changes were noted regarding mean amplitudes of EEG rhythms ( p > 0.05 for all ) . However , theta/SMR ratio showed a significant decrease at 4th week compared to baseline in the NFB group ( p < 0.05 ) . These data support the efficacy of NFB as a treatment for pain , psychological symptoms and impaired quality of life associated with fibromyalgia
While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .